• +1-646-491-9876
    • +91-20-67278686

    Search

    Anaplastic Astrocytoma-Pipeline Review H2 2017

    Anaplastic Astrocytoma-Pipeline Review H2 2017

    • Report Code ID: RW0001834368
    • Category Pharmaceuticals
    • No. of Pages 150
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Anaplastic Astrocytoma - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.

    Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes) , which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking and seizures. Anaplastic astrocytoma is common among men and women in their thirties to fifties and is more common in men than women. Treatment of anaplastic astrocytoma depends on the location of the tumor and how far it has progressed and usually involves surgery and radiation therapy, with chemotherapy during or following radiation.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Unknown stages are 4, 8, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.

    Anaplastic Astrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Anaplastic Astrocytoma - Overview 8
    Anaplastic Astrocytoma - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 16
    Anaplastic Astrocytoma - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 20
    Assessment by Route of Administration 22
    Assessment by Molecule Type 24
    Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 26
    Advantagene Inc 26
    Alfa Wassermann SpA 26
    Amgen Inc 27
    AngioChem Inc 27
    Astellas Pharma Inc 28
    Bayer AG 28
    Boehringer Ingelheim GmbH 29
    Burzynski Research Institute Inc 29
    Cavion LLC 30
    Celldex Therapeutics Inc 30
    Merrimack Pharmaceuticals Inc 31
    Millennium Pharmaceuticals Inc 31
    Novartis AG 32
    Orbus Therapeutics Inc 32
    Pfizer Inc 33
    Tocagen Inc 33
    Tragara Pharmaceuticals Inc 34
    TVAX Biomedical Inc 34
    ZIOPHARM Oncology Inc 35
    Anaplastic Astrocytoma - Drug Profiles 36
    (A-10 + AS-21) - Drug Profile 36
    Product Description 36
    Mechanism Of Action 36
    R&D Progress 36
    AdRTSIL-12 - Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    afatinib dimaleate - Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    alisertib - Drug Profile 62
    Product Description 62
    Mechanism Of Action 62
    R&D Progress 62
    BAY-1436032 - Drug Profile 68
    Product Description 68
    Mechanism Of Action 68
    R&D Progress 68
    bendamustine hydrochloride - Drug Profile 69
    Product Description 69
    Mechanism Of Action 69
    R&D Progress 69
    CDX-1401 - Drug Profile 73
    Product Description 73
    Mechanism Of Action 73
    R&D Progress 73
    Cellular Immunotherapy for Gliomas - Drug Profile 76
    Product Description 76
    Mechanism Of Action 76
    R&D Progress 76
    Cellular Immunotherapy for Oncology - Drug Profile 77
    Product Description 77
    Mechanism Of Action 77
    R&D Progress 77
    eflornithine hydrochloride - Drug Profile 78
    Product Description 78
    Mechanism Of Action 78
    R&D Progress 78
    flucytosine + TBio-01 - Drug Profile 80
    Product Description 80
    Mechanism Of Action 80
    R&D Progress 80
    flucytosine ER + vocimagene amiretrorepvec - Drug Profile 81
    Product Description 81
    Mechanism Of Action 81
    R&D Progress 81
    G-207 - Drug Profile 90
    Product Description 90
    Mechanism Of Action 90
    R&D Progress 90
    GliAtak - Drug Profile 92
    Product Description 92
    Mechanism Of Action 92
    R&D Progress 92
    irinotecan hydrochloride - Drug Profile 93
    Product Description 93
    Mechanism Of Action 93
    R&D Progress 93
    irinotecan hydrochloride + TBio-02 - Drug Profile 105
    Product Description 105
    Mechanism Of Action 105
    R&D Progress 105
    M-032 - Drug Profile 107
    Product Description 107
    Mechanism Of Action 107
    R&D Progress 107
    mibefradil dihydrochloride - Drug Profile 108
    Product Description 108
    Mechanism Of Action 108
    R&D Progress 108
    nilotinib - Drug Profile 111
    Product Description 111
    Mechanism Of Action 111
    R&D Progress 111
    p28 - Drug Profile 117
    Product Description 117
    Mechanism Of Action 117
    R&D Progress 117
    paclitaxel trevatide - Drug Profile 119
    Product Description 119
    Mechanism Of Action 119
    R&D Progress 119
    palbociclib - Drug Profile 124
    Product Description 124
    Mechanism Of Action 124
    R&D Progress 124
    procarbazine hydrochloride - Drug Profile 137
    Product Description 137
    Mechanism Of Action 137
    R&D Progress 137
    TBX.OncV NSC - Drug Profile 138
    Product Description 138
    Mechanism Of Action 138
    R&D Progress 138
    TG-02 - Drug Profile 139
    Product Description 139
    Mechanism Of Action 139
    R&D Progress 139
    TOT-302 - Drug Profile 142
    Product Description 142
    Mechanism Of Action 142
    R&D Progress 142
    TVI-Brain-1 - Drug Profile 143
    Product Description 143
    Mechanism Of Action 143
    R&D Progress 143
    Anaplastic Astrocytoma - Dormant Projects 145
    Anaplastic Astrocytoma - Discontinued Products 146
    Anaplastic Astrocytoma - Product Development Milestones 147
    Featured News & Press Releases 147
    Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 147
    Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 147
    Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 148
    Appendix 149
    Methodology 149
    Coverage 149
    Secondary Research 149
    Primary Research 149
    Expert Panel Validation 149
    Contact Us 149
    Disclaimer 150

    List of Tables

    Number of Products under Development for Anaplastic Astrocytoma, H2 2017 9
    Number of Products under Development by Companies, H2 2017 11
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017 12
    Number of Products under Development by Universities/Institutes, H2 2017 13
    Products under Development by Companies, H2 2017 14
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017 15
    Products under Development by Universities/Institutes, H2 2017 16
    Number of Products by Stage and Target, H2 2017 18
    Number of Products by Stage and Target, H2 2017 (Contd..1) , H2 2017 19
    Number of Products by Stage and Mechanism of Action, H2 2017 21
    Number of Products by Stage and Route of Administration, H2 2017 23
    Number of Products by Stage and Molecule Type, H2 2017 25
    Anaplastic Astrocytoma - Pipeline by Advantagene Inc, H2 2017 26
    Anaplastic Astrocytoma - Pipeline by Alfa Wassermann SpA, H2 2017 26
    Anaplastic Astrocytoma - Pipeline by Amgen Inc, H2 2017 27
    Anaplastic Astrocytoma - Pipeline by AngioChem Inc, H2 2017 27
    Anaplastic Astrocytoma - Pipeline by Astellas Pharma Inc, H2 2017 28
    Anaplastic Astrocytoma - Pipeline by Bayer AG, H2 2017 28
    Anaplastic Astrocytoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017 29
    Anaplastic Astrocytoma - Pipeline by Burzynski Research Institute Inc, H2 2017 29
    Anaplastic Astrocytoma - Pipeline by Cavion LLC, H2 2017 30
    Anaplastic Astrocytoma - Pipeline by Celldex Therapeutics Inc, H2 2017 30
    Anaplastic Astrocytoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 31
    Anaplastic Astrocytoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 32
    Anaplastic Astrocytoma - Pipeline by Novartis AG, H2 2017 32
    Anaplastic Astrocytoma - Pipeline by Orbus Therapeutics Inc, H2 2017 33
    Anaplastic Astrocytoma - Pipeline by Pfizer Inc, H2 2017 33
    Anaplastic Astrocytoma - Pipeline by Tocagen Inc, H2 2017 33
    Anaplastic Astrocytoma - Pipeline by Tragara Pharmaceuticals Inc, H2 2017 34
    Anaplastic Astrocytoma - Pipeline by TVAX Biomedical Inc, H2 2017 34
    Anaplastic Astrocytoma - Pipeline by ZIOPHARM Oncology Inc, H2 2017 35
    Anaplastic Astrocytoma - Dormant Projects, H2 2017 145
    Anaplastic Astrocytoma - Discontinued Products, H2 2017 146

    List of Figures

    Number of Products under Development for Anaplastic Astrocytoma, H2 2017 9
    Number of Products under Development by Companies, H2 2017 10
    Number of Products under Development by Universities/Institutes, H2 2017 13
    Number of Products by Top 10 Targets, H2 2017 17
    Number of Products by Stage and Top 10 Targets, H2 2017 17
    Number of Products by Top 10 Mechanism of Actions, H2 2017 20
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 20
    Number of Products by Routes of Administration, H2 2017 22
    Number of Products by Stage and Routes of Administration, H2 2017 22
    Number of Products by Molecule Types, H2 2017 24
    Number of Products by Stage and Molecule Types, H2 2017 24
    Advantagene Inc
    Alfa Wassermann SpA
    Amgen Inc
    AngioChem Inc
    Astellas Pharma Inc
    Bayer AG
    Boehringer Ingelheim GmbH
    Burzynski Research Institute Inc
    Cavion LLC
    Celldex Therapeutics Inc
    Merrimack Pharmaceuticals Inc
    Millennium Pharmaceuticals Inc
    Novartis AG
    Orbus Therapeutics Inc
    Pfizer Inc
    Tocagen Inc
    Tragara Pharmaceuticals Inc
    TVAX Biomedical Inc
    ZIOPHARM Oncology Inc

    Request for Sample

    Report Url http://www.reportsweb.com//anaplastic-astrocytoma-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//anaplastic-astrocytoma-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//anaplastic-astrocytoma-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments